These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 28502608)

  • 21. Biosimilars in inflammatory bowel disease: A review of post-marketing experience.
    Deiana S; Gabbani T; Annese V
    World J Gastroenterol; 2017 Jan; 23(2):197-203. PubMed ID: 28127193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases.
    Komaki Y; Yamada A; Komaki F; Micic D; Ido A; Sakuraba A
    Aliment Pharmacol Ther; 2017 Apr; 45(8):1043-1057. PubMed ID: 28239873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biosimilar Monoclonal Antibodies for Inflammatory Bowel Disease: Current Comfort and Future Prospects.
    Gecse KB; Lakatos PL
    Drugs; 2016 Oct; 76(15):1413-1420. PubMed ID: 27638739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 'wind of change' to biosimilars: The NOR-SWITCH trial and its extension.
    Kay J
    J Intern Med; 2019 Jun; 285(6):693-695. PubMed ID: 30990229
    [No Abstract]   [Full Text] [Related]  

  • 25. Does the Introduction of Biosimilars Change Our Understanding about Treatment Modalities for Inflammatory Bowel Disease?
    Buer L; Høivik ML; Medhus AW; Moum B
    Dig Dis; 2017; 35(1-2):74-82. PubMed ID: 28147370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An update on biosimilar drugs for inflammatory bowel disease.
    Schreiber S
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():1-3. PubMed ID: 26395529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Anti-TNF biosimilars in chronic inflammatory bowel disease. What can rheumatologists learn from it?].
    Schreiber S
    Z Rheumatol; 2015 Oct; 74(8):689-94. PubMed ID: 26450434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review.
    Radin M; Sciascia S; Roccatello D; Cuadrado MJ
    BioDrugs; 2017 Feb; 31(1):37-49. PubMed ID: 28035633
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-Life Efficacy, Immunogenicity and Safety of Biosimilar Infliximab.
    Vegh Z; Kurti Z; Lakatos PL
    Dig Dis; 2017; 35(1-2):101-106. PubMed ID: 28147369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ANVISA APPROVES THE FIRST BIOSIMILAR MONOCLONAL ANTIBODY BASED ON COMPARABILITY IN BRAZIL.
    Teixeira FV; Kotze PG; Damião AO
    Arq Gastroenterol; 2016; 53(2):60-1. PubMed ID: 27305409
    [No Abstract]   [Full Text] [Related]  

  • 31. The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13.
    Reinisch W; Louis E; Danese S
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():17-26. PubMed ID: 26395531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biosimilars in inflammatory bowel disease.
    Gargallo CJ; Lué A; Gomollón F
    Minerva Med; 2017 Jun; 108(3):239-254. PubMed ID: 28176515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
    Kolar M; Duricova D; Bortlik M; Hruba V; Machkova N; Mitrova K; Malickova K; Lukas M; Lukas M
    Dig Dis; 2017; 35(1-2):91-100. PubMed ID: 28147356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience.
    Ratnakumaran R; To N; Gracie DJ; Selinger CP; O'Connor A; Clark T; Carey N; Leigh K; Bourner L; Ford AC; Hamlin PJ
    Scand J Gastroenterol; 2018 Jun; 53(6):700-707. PubMed ID: 29687730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biosimilar infliximab: an expert view.
    Genazzani A; Altomare G; Balato N; Cusano F; De Pità O; Loconsole F; Micali G; Piaserico S; Girolomoni G
    G Ital Dermatol Venereol; 2015 Aug; 150(4):449-59. PubMed ID: 25747260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease.
    Farkas K; Molnár T
    Immunotherapy; 2018 Feb; 10(2):107-117. PubMed ID: 29124994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experience with Biosimilar Infliximab (Remsima®) in Norway.
    Jahnsen J; Kaasen Jørgensen K
    Dig Dis; 2017; 35(1-2):83-90. PubMed ID: 28147374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients.
    Fiorino G; Correale C; Radice S; Allocca M; Furfaro F; Gilardi D; Nagore D; Del Rio L; Pascual J; Martínez A; Danese S
    Aliment Pharmacol Ther; 2017 Nov; 46(9):903-905. PubMed ID: 29023889
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.
    Gecse KB; Lovász BD; Farkas K; Banai J; Bene L; Gasztonyi B; Golovics PA; Kristóf T; Lakatos L; Csontos ÁA; Juhász M; Nagy F; Palatka K; Papp M; Patai Á; Lakner L; Salamon Á; Szamosi T; Szepes Z; Tóth GT; Vincze Á; Szalay B; Molnár T; Lakatos PL
    J Crohns Colitis; 2016 Feb; 10(2):133-40. PubMed ID: 26661272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update of the SEPD position statement on the use of biosimilars for inflammatory bowel disease.
    Argüelles Arias F; Hinojosa Del Val J; Vera Mendoza I
    Rev Esp Enferm Dig; 2018 Jun; 110(6):407. PubMed ID: 29527903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.